Table 2.
Baseline clinical characteristics of treatment-naïve and early-disease IIM patients treated with standard-of-care pharmacological therapy: longitudinal cohort 1.
| Parameters | Baseline (Month 0) (n=39) | Month 6 (n=39) | Month 12 (n=39) |
|---|---|---|---|
| Sex: Female/Male, n (%) | 29 (74)/10 (26) | ||
| Age, years | 57.1 (53.2 – 63.3) | ||
| Clinical features | |||
| Disease duration, months | 1.2 (0.0 – 2.8) | ||
| IIM subtype, n (%): PM/DM/ | 13 (33)/18 (46)/ | ||
| IMNM | 8 (21) | ||
| IIM-associated symptoms, n (%): MW/SR/MH/ | 39 (100)/24 (62)/14 (36)/ | ||
| RP/A/ILD/ | 10 (26)/10 (26)/26 (67)/ | ||
| CI/D | 8 (21)/21 (54) | ||
| MITAX | 0.2 (0.1 – 0.3) | ||
| MYOACT | 0.1 (0.03 – 0.2) | ||
| MDI extent | 0.11 (0.03 – 0.13) | ||
| MMT-8 | 65.0 (55.0 – 71.0) | ||
| HAQ | 0.9 (0.4 – 1.4) | ||
| Laboratory features | |||
| Autoantibodies, n (%): ANA/Ro-52/Jo-1/TIF1/ | 15 (38)/11 (28)/11 (28)/1 (3)/ | ||
| PM-Scl/Mi-2/HMGCR/Ro-60/SRP/U1RNP | 4 (10)/4 (10)/4 (10)/3(7)//2 (6)/1 (3) | ||
| CRP, mg/L | 2.7 (1.3 – 8.1) | 2.2 (1.0 – 8.6) | 1.6 (0.9 – 15.0) |
| CK, μkat/L | 3.8 (1.3 – 18.3) | 1.4 (0.6 – 7.3) | 1.4 (0.7 – 3.7) |
| LD, μkat/L | 5.9 (4.0 – 8.5) | 4.0 (3.5 – 6.2) | 4.1 (3.0 – 4.9) |
| Current treatment: | |||
| Prednisone equivalent dose, mg/day | 20 (0 – 50) | 20 (10 – 25) | 10 (7.5 – 20) |
| MTX/AZA, n (%) | 9 (23)/3 (8) | 14 (36)/5 (13) | 12 (31)/9 (23) |
Data are presented as median (inter-quartile range) unless stated otherwise; A, arthritis; ANA, antinuclear antibodies; AZA, azathioprine; CDM, cancer-associated dermatomyositis; CI, cardiac involvement; CK, creatine kinase; CRP, C-reactive protein; D, dysphagia; DM, dermatomyositis; HAQ, Health Assessment Questionnaire; HMGCR, anti-3-hydroxy-3-methylglutaryl-CoA reductase; IIM, idiopathic inflammatory myopathy; ILD, interstitial lung disease; IMNM, immune-mediated necrotizing myopathy; Jo-1, anti-histidyl-tRNA synthetase; LD, lactate dehydrogenase; MDI, Myositis Damage Index; MH, mechanic’s hands; Mi-2, antinuclear helicase 218/240 kDa; MITAX, Myositis Intention to Treat Activity Index; MMT-8, Manual Muscle Testing of eight muscles; MTX, methotrexate; MW, muscle weakness; MYOACT, Myositis Disease Activity Assessment visual analogue scale; PM, polymyositis; PM-Scl, anti-Pm-Scl (anti-core complex 11-16 proteins); Ro, anti-Ro (52/60kDa, against cytoplasmic RNA and associated peptides); RP, Raynaud’s phenomenon; SR, skin rash; SRP, anti-signal recognition particles; TIF1, anti-TIF1 (transcription intermediary factor-1); U1RNP, anti-u1-rnp (ribonucleoprotein).